We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA will be working with Duke University's Clinical Research Institute to develop biomarkers identifying potential cardiac side effects from certain drugs and devices.
The UK's National Institute of Health and Clinical Excellence (NICE) has issued guidance to the National Health Service (NHS) in England in Wales recommending Roche's MabThera (rituximab), within its licensed indications, as an option for the treatment of patients with symptomatic Stage III and IV follicular lymphoma who have previously been untreated.
Ranbaxy Laboratories has announced that its wholly owned subsidiary, Ranbaxy Malaysia, has launched the first generic Atorvastatin, a statin, under the brand name Storvas in Malaysia.
Teva Pharmaceutical Industries Ltd. and Protalix Biotherapeutics Ltd. have signed a collaboration and licensing agreement for the development of two proteins, using Protalix's plant cell culture platform.
Shares of British biotechnology company SR Pharma PLC surged Tuesday after the company said its Atugen AG subsidiary will receive payments of up to US$95 million (€74.3 million) as well as royalties as a result of entering into a licensing agreement with Pfizer Inc. and Quark Biotech Inc.
Indian Pharmaceutical Association (IPA) has claimed that their member associations have voluntarily cut down the trade margins on generic drugs exclusively promoted through trade route, resulting in a price reduction in the range of 2 to 70 per cent on these drugs.
Elan Corporation, plc ("Elan") and Transition Therapeutics Inc. ("Transition"), today announced an exclusive, worldwide collaboration agreement for the joint development and commercialization of a novel therapeutic agent, AZD-103, for the treatment of Alzheimer's disease.
A southern Indian court judge on Tuesday referred a patent dispute over the popular cancer drug Gleevec to a two-judge tribunal, saying the importance of the questions involved required a larger panel, according to a lawyer.
The dangerous side effects of an HIV drug commonly used in South Africa have forced medical experts to reevaluate the limited treatment options available in developing countries, reports the UN Integrated Regional Information Networks (IRIN).